Brought to you by 
Pelikan closes $29.2mm Series D round
26 Oct 2004
Executive Summary
Pelikan Technologies (develops handheld diagnostics) raised $29.2mm through a private placement of Series D preferred stock led by Swissfirst Bank AG. Returning shareholders HBM BioVentures, Mannheim, and Heidelberg Innovation also participated along with new individual investors.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Glucose Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pelikan closes $29.2mm Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice